Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

The anti-CCP antibody results correlated with RF, but were better than RF as predictor of a more aggressive disease course. After 3 years 5/97 patients had changed anti-CCP status: 2 from negative to ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Dr. James Hansen, a Yale Cancer Center researcher, and his team discovered that using an antibody related to lupus they can breach the tumor and trigger an immune response to fight it. He says ...

1Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts. *Corresponding Author: Adnan O. Abu-Yousif, Oncology Drug ...

Of the candidates that the San Diego-based company is now prioritizing for internal development, the most advanced is an anti-AXL antibody-drug conjugate called mecbotamab vedotin. BioAtla said ...